The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Christopher Manley and Kristen Scully Manley join Fox Chase

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

CHRISTOPHER MANLEY and KRISTEN SCULLY MANLEY joined Fox Chase Cancer Center.

Christopher Manley will serve as the director of interventional pulmonology in the Department of Medicine, and Kristen Scully Manley will serve as a hospitalist in the department of medicine.

“Dr. Manley’s expertise in pulmonary medicine makes him the perfect candidate for our new director of interventional pulmonology,” said David Weinberg, chair of the department of medicine.

He will join Fox Chase after finishing his interventional pulmonology fellowship at Beth Israel Deaconess Medical Center and Massachusetts General Hospital this summer.

Scully Manley most recently served as a member of the hospitalist team in the division of general medicine and primary care at Beth Israel Deaconess, where she was honored as Clinician of the Year in 2015.

Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
By Claire Marie Porter
Guest Editorial

Regulation must keep up with scientific advances

The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
By Richard M. Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account